{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:31:03Z","timestamp":1783600263394,"version":"3.55.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>During the course of multiple myeloma (MM), new monoclonal proteins of an isotype distinct from the original clone, referred to as secondary monoclonal gammopathy of undetermined significance (MGUS), have been described. We report on the frequency, characteristics, and outcome of secondary MGUS. Of the 1942 patients with MM, 128 (6.6%) developed a secondary MGUS, at a median of 12 months from the diagnosis of MM. The median duration of secondary MGUS was 5.9 months. Secondary MGUS was more common in patients after stem cell transplantation than in those who had not undergone such treatment (22.7% vs 1.6%, P &amp;lt; .001). Overall survival was significantly superior in MM patients who developed secondary MGUS compared with the rest of the cohort (73 vs 38 months, respectively; P &amp;lt; .001). The time of onset and the duration of secondary MGUS, as well as failure to resolve spontaneously, had an effect on overall survival and require further study.<\/jats:p>","DOI":"10.1182\/blood-2011-04-349175","type":"journal-article","created":{"date-parts":[[2011,7,16]],"date-time":"2011-07-16T02:24:13Z","timestamp":1310783053000},"page":"2985-2987","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma"],"prefix":"10.1182","volume":"118","author":[{"given":"Rishi K.","family":"Wadhera","sequence":"first","affiliation":[{"name":"Department of Medicine, Mayo Medical School, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk R.","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Mayo Clinic, Rochester, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"University Hospitals Case Medical Center and the Ireland Cancer Center and Case Comprehensive Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020071610022923200_B1","first-page":"1184","article-title":"Plasma cell disorders.","volume-title":"Cecil Textbook of Medicine","author":"Kyle","year":"2004","edition":"22nd ed"},{"key":"2020071610022923200_B2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/asheducation-2005.1.340","article-title":"MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.","author":"Rajkumar","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2020071610022923200_B3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"issue":"10","key":"2020071610022923200_B4","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4065\/mcp.2010.0337","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: a systematic review.","volume":"85","author":"Wadhera","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2020071610022923200_B5","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2020071610022923200_B6","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0025-6196(11)61090-2","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan.","volume":"82","author":"Iwanaga","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"13","key":"2020071610022923200_B7","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance.","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"2020071610022923200_B8","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","article-title":"Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana.","volume":"82","author":"Landgren","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2020071610022923200_B9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/jcp.35.1.63","article-title":"Monoclonal gammopathies in the adult population of Finistere, France.","volume":"35","author":"Saleun","year":"1982","journal-title":"J Clin Pathol"},{"issue":"25","key":"2020071610022923200_B10","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1182\/blood-2009-02-203471","article-title":"Pesticide exposure and risk of monoclonal gammopathy of undetermined significance (MGUS) in the Agricultural Health Study.","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"18","key":"2020071610022923200_B11","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma.","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"2020071610022923200_B12","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma.","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2020071610022923200_B13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4065\/79.7.859","article-title":"Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later.","volume":"79","author":"Kyle","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"2020071610022923200_B14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance.","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"2020071610022923200_B15","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/leu.2008.203","article-title":"Pathogenesis and progression of monoclonal gammopathy of undetermined significance.","volume":"22","author":"Blade","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"2020071610022923200_B16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"2020071610022923200_B17","doi-asserted-by":"crossref","article-title":"\u201cSecondary MGUS\u201d after high-dose melphalan and autologous hematopoietic progenitor cell transplantation in multiple myeloma: a matter of undetermined significance.","author":"Manson","DOI":"10.1182\/blood.V116.21.1296.1296"},{"issue":"8","key":"2020071610022923200_B18","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood.V74.8.2764.2764","article-title":"Monoclonal and oligoclonal gammopathy after bone marrow transplantation.","volume":"74","author":"Mitus","year":"1989","journal-title":"Blood"},{"issue":"3","key":"2020071610022923200_B19","first-page":"225","article-title":"Isotype class switching after transplantation in multiple myeloma.","volume":"54","author":"Maisnar","year":"2007","journal-title":"Neoplasma"},{"issue":"9","key":"2020071610022923200_B20","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1182\/blood.V91.9.3518","article-title":"Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation.","volume":"91","author":"Zent","year":"1998","journal-title":"Blood"},{"issue":"1","key":"2020071610022923200_B21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"2020071610022923200_B22","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma.","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2020071610022923200_B23","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2141.2008.07374.x","article-title":"Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.","volume":"143","author":"Mark","year":"2008","journal-title":"Br J Haematol"},{"issue":"5","key":"2020071610022923200_B24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1515\/CCLM.2010.050","article-title":"Oligoclonal bands and immunoglobulin isotype switch during monitoring of patients with multiple myeloma and autologous hematopoietic cell transplantation: a 16-year experience.","volume":"48","author":"Alejandre","year":"2010","journal-title":"Clin Chem Lab Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/11\/2985\/1341398\/zh803711002985.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/11\/2985\/1341398\/zh803711002985.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T12:48:12Z","timestamp":1594903692000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/11\/2985\/28451\/Incidence-clinical-course-and-prognosis-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,15]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,9,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-04-349175","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13357295.14726681","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,15]]}}}